Research

Energy balance

Metabolomic subtypes have shown potential in guiding treatment selection for obesity.

Practitioners can consider metabolomic profiles to tailor obesity treatments.

StrongSupportsmedium confidence
Metabolomic subtypes, including ceramide driven insulin resistance and branched chain amino acid (BCAA) dominant dysregulation, have shown potential in guiding treatment selection, such as sodium glucose cotransporter 2 (SGLT2) inhibitors or glucagon like peptide-1 (GLP-1) agonists.
Mohammad Mustafa et al. · Molecular Omics · 2025

Why this rating

The claim is based on research findings regarding treatment selection.

Source

The omics revolution in obesity: from molecularsignatures to clinical solutions

Mohammad Mustafa et al. · Molecular Omics · 2025

DOI 10.1039/d5mo00074b

reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →